JP Morgan Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $10
JP Morgan analyst Anupam Rama initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Overweight rating and announces Price Target of $10.
Share
Why It Matters
A big bank's analyst says C4 Therapeutics stock looks good to buy. This means the analyst thinks the company has a promising future.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.